Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
IBRX
Stock Latest News
The Fly
Unusually active option classes on open October 1st
18d ago
AES
BMY
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
1M ago
JNJ
CGON
Premium
Ratings
Promising Developments in ImmunityBio’s ANKTIVA for NSCLC: A Buy Rating Based on Lymphorestorative Potential and Broader Oncology Applications
1M ago
IBRX
Premium
Ratings
Buy Rating for ImmunityBio’s ANKTIVA: Promising Phase II Results and Potential Biomarker Identification
1M ago
IBRX
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
1M ago
JNJ
CGON
Premium
The Fly
ImmunityBio study shows ANKTIVA reverses lymphopenia, extends survival
1M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?
1M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?
1M ago
IBRX
Premium
The Fly
ImmunityBio announces early findings from Anktiva pilot study
2M ago
IBRX
Premium
The Fly
ImmunityBio announces Anktiva trial
2M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
2M ago
IBRX
Premium
The Fly
ImmunityBio announces early findings from QUILT-106 trial
2M ago
IBRX
Premium
The Fly
ImmunityBio says VA hospital among first to administer ANKTIVA
2M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
2M ago
8K
IBRX
Premium
Ratings
ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating
2M ago
IBRX
Premium
Company Announcements
ImmunityBio Reports Revenue Growth Amidst Continued Investments
2M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update
3M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment
3M ago
IBRX
Premium
Company Announcements
ImmunityBio Announces $80 Million Securities Purchase
3M ago
8K
IBRX
Premium
The Fly
ImmunityBio reports Q2 revenue $26.4M, consensus $21.95M
3M ago
IBRX
Premium
The Fly
ImmunityBio announces $80M registered direct offering
3M ago
IBRX
Premium
Company Announcements
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update
3M ago
IBRX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
